INCY - Incyte Corporation

-

$undefined

N/A

(N/A)

Incyte Corporation NASDAQ:INCY Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics.

Location: 1801 Augustine Cut off, Delaware, 19803-4404, US | Website: www.incyte.com | Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) | Sector: Professional, Scientific, and Technical Services


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

12.25B

Cash

1.775B

Avg Qtr Burn

N/A

Short % of Float

3.19%

Insider Ownership

2.05%

Institutional Own.

97.43%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Metastatic merkel cell carcinoma, Skin cancer

Approved

Quarterly sales

Niktimvo™ (axatilimab-csfr) Details
Graft-versus-host disease

Approved

Quarterly sales

Pemazyre® (pemigatinib) Details
8p11 myeloproliferative syndrome

Approved

Quarterly sales

ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Squamous cell carcinoma of the anal canal

BLA

Submission

Tafasitamab (Monjuvi®) + Lenalidomide & Rituximab Details
Follicular lymphoma, Relapsed/ refractory lymphoma

BLA

Submission

ZYNYZ (Retifanlimab) (anti-PD-1 mAb) Details
Solid tumor/s, Cancer, Non-small cell lung carcinoma

BLA

Submission

NDA

FDA meeting

Phase 3

Data readout

Povorcitinib (JAK1) Details
Hidradenitis suppurativa

Phase 3

Data readout

Phase 3

Data readout

Phase 3

Initiation

Phase 3

Initiation

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 2

Data readout

Phase 1

Data readout

Phase 1

Data readout

Failed

Discontinued

Failed

Discontinued